News | October 23, 2023
RPG Life Sciences posts Q2 FY24 PAT at Rs. 25.86 Cr
RPG Life Sciences has reported total income of Rs. 155.41 crores during the period ended September 30, 2023
RPG Life Sciences has reported total income of Rs. 155.41 crores during the period ended September 30, 2023
Investment is additive to KKR’s existing health care growth strategy
Will continue to own a 7.84 per cent stake in Glenmark Life Sciences with the stake reduction
ABB India has secured an order from Reliance Life Sciences to deploy automation and control solutions for their new biosimilars and plasma proteins manufacturing facilities in Nashik, Maharashtra
Combination creates an integrated provider of drug development and regulatory consulting services serving a complementary client base
Suven Life Sciences has reported total income of Rs. 9.43 crores during the period ended June 30, 2023
Contracts are related to a $487 million biotech expansion project in Denmark and first phase of a new life sciences production facility valued at $574 million in Central U.S.
The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.
The newly launched Genomic Health Insights (GHI) program to make sequencing accessible to all
Suven Life Sciences completed enrollment of patients to the phase-2, PoC clinical study of samelisant (SUVN-G3031) for the treatment of narcolepsy with or without cataplexy in USA and Canada
Subscribe To Our Newsletter & Stay Updated
